Emmaus Life Sciences Reports Q2 2023 Financial ResultsAugust 14, 2023
Emmaus Life Sciences, Inc. today reported on its financial condition and results of operations as of and for the three and six months ended June 30, 2023.
Read MoreEmmaus Life Sciences, Inc. today reported on its financial condition and results of operations as of and for the three and six months ended June 30, 2023.
Read MoreEmmaus today announced that it has received marketing authorization from the Oman Ministry of Health for the commercial distribution and sale of Endari®
Read MoreEmmaus has received a Medicine Registration Certificate (DRN-10164/23) from the Bahrain National Health Regulatory Authority (NHRA) granting marketing authorization for the commercial distribution and sale of Endari® in the Kingdom of Bahrain.
Read MoreEmmaus Life Sciences, Inc. today reported on its financial condition and results of operations as of and for the three months ended March 31, 2023.
Read MoreEmmaus announced today preliminary results for the 3 months that ended March 31, 2023.
Read More